Depacon

(Valproate)

ApprovedSmall molecule

AbbVie

Depacon is one of 441 small molecule programs targeting Enuresis. It is currently in Approved.

Indications

Total Trials

Active Trials

440

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

EnuresisActive, not recruiting

Bipolar I DisorderActive, not recruiting

DeliriumActive, not recruiting

PneumoniaActive, not recruiting

SeizureActive, not recruiting

GlioblastomaActive, not recruiting

Diffuse Large B-Cell LymphomaActive, not recruiting

Chronic Lymphocytic LeukemiaActive, not recruiting

MigraineActive, not recruiting

EpilepsyActive, not recruiting

EnuresisPreclinical

Active, not recruiting

Bipolar I DisorderPhase 3

Active, not recruiting

DeliriumPhase 2/Phase 3

Active, not recruiting

PneumoniaApproved

Active, not recruiting

SeizurePhase 1/Phase 2

Active, not recruiting

GlioblastomaPhase 1

Active, not recruiting

Diffuse Large B-Cell LymphomaPhase 1/Phase 2

Active, not recruiting

Chronic Lymphocytic LeukemiaPhase 1

Active, not recruiting

MigraineApproved

Active, not recruiting

EpilepsyPhase 3

Active, not recruiting

Showing 10 of 15 indications

Competition

Competitive Landscape

583 competitors in Schizophrenia

#DrugCompanyPhaseTrials

Depacon

AbbVie

Approved

1 2

Celexa

AbbVie

Preclinical

4 3

Ozempic

Novo Nordisk

Preclinical

1 4

Resotran

Takeda

Preclinical

1 5

Inapsine

Alnylam Pharmaceuticals

Preclinical

1 6

Depakote

Ibrance

Comtan

Orion Corporation, Orion Pharma

Preclinical

1 9

Inversine

TTargacept Inc.

Preclinical

1 10

Permax

VValeant Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2/3Recruiting

Delirium

NCT05431595

Q2 2027

Phase 3Recruiting

Mania

NCT07140913

Q3 2027

Phase 1/2Not yet recruiting

Amblyopia

NCT07226141

Q2 2028

Phase 3Recruiting

Bipolar Disorder

NCT06929273

Clinical

Trials by Indication[1]

Bipolar Disorder6 trials

Add-on Dextromethorphan in Bipolar Disorders

Completed·NNational Cheng-Kung University Hospital·Phase 3·NCT01188265·300 enrolled

Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)

Completed·NNational Institute of Mental Health (NIMH)·N/A·NCT00012558·5,000 enrolled

ABLE: Abilify in Bipolar Disorder for Long-term Effectiveness

Completed·KKorea Otsuka International Asia Arab·Phase 4·NCT00484471·127 enrolled

Show 3 more trials

Decision-Making in Bipolar Disorder

Completed·EEmory University·N/A·NCT01463111·37 enrolled

Placebo Controlled Trial of Valproate and Risperidone in Young Children With Bipolar Disorders

Completed·—·Phase 3·NCT00221403·46 enrolled

A Phase 3, Open-label Extension Study to Assess the Long-term Safety of KarXT for the Treatment of Mania or Mania With Mixed Features in Bipolar-I Disorder (BALSAM-3)

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT06929273·450 enrolled

Withdrawal3 trials

The Effect of Valproate on Benzodiazepine Withdrawal Severity

Completed·UUniversity of Helsinki·N/A·NCT00570219·30 enrolled

Assessment of Valproate on Ethanol Withdrawal

Unknown status·—·Phase 4·NCT03235531·210 enrolled

Treatment of Polydrug-Using Opiate Dependents During Withdrawal

Completed·SSorlandet Hospital HF·Phase 4·NCT00367874·12 enrolled

Adolescent2 trials

Study of Outcome and Safety of Lithium, Divalproex and Risperidone for Mania in Children and Adolescents

Completed·WWashington University School of Medicine·Phase 3·NCT00057681·379 enrolled

Valproate Response in Aggressive Autistic Adolescents

Unknown status·EEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·Phase 3·NCT00065884·30 enrolled

Status Epilepticus2 trials

Phenobarbital Versus Valproate for Generalized Convulsive Status Epilepticus

Unknown status·XXuanwu Hospital, Beijing·Phase 2·NCT03025906·120 enrolled

Safety and Efficacy of Intravenous Valproate in Pediatric Status Epilepticus and Acute Repetitive Seizures

Unknown status·HHillel Yaffe Medical Center··NCT01268904·50 enrolled

Bipolar I Disorder2 trials

Study to Evaluate the Efficacy and Safety of Aripiprazole Administered With Lithium or Valproate Over 12 Weeks in the Treatment of Mania in Bipolar I Disorder

Completed· Otsuka logo

Otsuka·Phase 3·NCT00665366·493 enrolled

Efficacy and Safety of Olanzapine in the Extended Treatment for Manic or Mixed Episode of Bipolar I Disorder

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00266630·139 enrolled

26 more indications

Seizure2 trials

A Dose Ranging Pilot Study for Intracerebroventricular (ICV) Delivery of Valproate in Subjects With Temporal Seizures

Completed·CCerebral Therapeutics LLC·Phase 1/2·NCT02899611·6 enrolled

Levetiracetam Versus Valproate in Idiopathic Generalized Tonic-clonic Seizures

Completed·MMazandaran University of Medical Sciences·Phase 4·NCT03940326·103 enrolled

Pneumonia1 trial

Valproate Alone or in Combination With Quetiapine for Severe COVID-19 Pneumonia With Agitated Delirium

Withdrawn·UUniversity of Miami·Phase 4·NCT04513314

Amblyopia1 trial

Valproate for the Treatment of Residual Amblyopia

Not yet recruiting·—·Phase 1/2·NCT07226141·28 enrolled

TIPS1 trial

Determining Metabolic Effects of Valproate and Antipsychotic Therapy

Completed·WWashington University School of Medicine·N/A·NCT00167934·164 enrolled

Diffuse Large B-Cell Lymphoma1 trial

Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma

Completed·LLund University Hospital·Phase 1/2·NCT01622439·50 enrolled

Acceptability1 trial

Comparative Efficacy and Acceptability of Antimanic Drugs in Acute Mania

Unknown status·GGuiyun Xu·Phase 4·NCT01893229·120 enrolled

Delirium1 trial

Managing Agitated Delirium With Neuroleptics and Anti-Epileptics as a Neuroleptic Sparing Strategy

Recruiting·MM.D. Anderson Cancer Center·Phase 2/3·NCT05431595·42 enrolled

Effectiveness1 trial

Effectiveness of Combined Medication Treatment for Aggression in Children With Attention Deficit With Hyperactivity Disorder (The SPICY Study)

Unknown status·JJoseph Blader·Phase 4·NCT00794625·270 enrolled

Tics1 trial

A Study on the Effects of Valproate on the Pharmacokinetics of RO4917838 in Healthy Volunteers

Completed· Roche logo

Roche·Phase 1·NCT01495104·18 enrolled

Maintenance Treatment1 trial

Atypical Antipsychotics for Continuation and Maintenance Treatment After an Acute Manic Episode

Completed·UUniversity of British Columbia·Phase 3·NCT01977300·159 enrolled

Glioblastoma1 trial

Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma

Terminated·UUniversity of Virginia·Phase 1·NCT02648633·4 enrolled

Migraine1 trial

Zolmitriptane as Prophylaxis for Chilhood Migraine

Unknown status·TTanta University·Phase 4·NCT06089356·90 enrolled

Schizophrenia1 trial

Valproate in Late Life Schizophrenia

Completed·UUniversity Hospitals Cleveland Medical Center·Phase 4·NCT00194025·20 enrolled

Alcohol Use Disorders1 trial

Treatment Strategy for Alcohol Use Disorders in Veterans With TBI

Completed·VVA Office of Research and Development·Phase 3·NCT01342549·62 enrolled

Morbidity1 trial

Valproate Efficacy in Cocaine-Bipolar Comorbidity

Completed·UUniversity of Miami·Phase 1/2·NCT00240110·152 enrolled

Agitation1 trial

Haloperidol vs. Valproate in Agitation

Completed·SShahid Beheshti University of Medical Sciences·Phase 3·NCT01750541·56 enrolled

Chronic Lymphocytic Leukemia1 trial

Pretreatment With Valproate Prior to Immunotherapy Targeting Cluster of Differentiation Antigen 20 in Chronic Lymphocytic Leukemia

Completed·LLund University Hospital·Phase 1·NCT02144623·4 enrolled

Interaction1 trial

Drug-drug Interaction Between Ciprofol and Mefanamic Acid or Valproate

Completed· Haisco Pharmaceutical Group Co., Ltd. logo

Haisco Pharmaceutical Group Co., Ltd.·Phase 1·NCT05181007·41 enrolled

Bipolar Depression1 trial

Cytidine- and Creatine-Containing Drug in Treating Bipolar Depression

Withdrawn·EEwha Womans University·Phase 2·NCT01543139

Dementia1 trial

Valproate in Dementia (VALID)

Completed·AAlzheimer's Disease Cooperative Study (ADCS)·Phase 3·NCT00071721·313 enrolled

Drug1 trial

Antiepileptic Drugs and Vascular Risk Markers

Terminated·TThomas Jefferson University·N/A·NCT00774306·52 enrolled

Enuresis1 trial

Sleep Architecture in Valproate-induced Nocturnal Enuresis in Primary School and Preschool Children.

Completed·MMansoura University Hospital··NCT04191863·260 enrolled

Brain Metastases1 trial

Valproate and Etoposide for Patients With Neuronal Tumors and Brain Metastases

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00513162·8 enrolled

Ketorolac1 trial

Valproate Versus Ketorolac Versus Metoclopramide

Completed·MMontefiore Medical Center·Phase 4·NCT01267864·330 enrolled

Epilepsy1 trial

Levetiracetam Versus Standard Antiepileptic Drugs (Carbamazepine and Valproate) Used as Monotherapy in Patients With Newly Diagnosed Epilepsy

Completed· UCB logo

UCB·Phase 3·NCT00175903·1,701 enrolled

Mania1 trial

A Phase 3, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Individuals With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT07140913·424 enrolled

Regulatory

FDA Approval Timeline[4]

Dec 30, 1996

DEPACON

NDA NDA020593

Sources

References

[1]
ClinicalTrials.gov — 42 trial records for Valproate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Valproate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Valproate. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA020593). U.S. Food & Drug Administration.
[5]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: AbbVie

Depacon

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2027

Q3 2027

Q2 2028

Trials by Indication[1]

Bipolar Disorder6 trials

Withdrawal3 trials

Adolescent2 trials

Status Epilepticus2 trials

Bipolar I Disorder2 trials

Seizure2 trials

Pneumonia1 trial

Amblyopia1 trial

TIPS1 trial

Diffuse Large B-Cell Lymphoma1 trial

Acceptability1 trial

Delirium1 trial

Effectiveness1 trial

Tics1 trial

Maintenance Treatment1 trial

Glioblastoma1 trial

Migraine1 trial

Schizophrenia1 trial

Alcohol Use Disorders1 trial

Morbidity1 trial

Agitation1 trial

Chronic Lymphocytic Leukemia1 trial

Interaction1 trial

Bipolar Depression1 trial

Dementia1 trial

Drug1 trial

Enuresis1 trial

Brain Metastases1 trial

Ketorolac1 trial

Epilepsy1 trial

Mania1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News